TokenPost·
Starling Oncology, Inc. Revenue Beats Estimates by $1.11 Million in Q3
The company posted a 14-cent GAAP loss per share and positive adjusted EBITDA of $3.4 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30.
More news
- TokenPost[Wall Street liquidity radar] Bitcoin’s US discount and bearish positioning persist as institutional volume drops
- TokenPost[Global liquidity radar] Exchanges shed 1,746 BTC as Asia volume rises 64%, US drops 87%
- BeInCryptoBitcoin Developer Proposes a Quantum Trap for Hackers
- TokenPostHyperliquid Strategies Seeks CFTC Registration for U.S. Accounts
- TokenPost[Bitcoin now] Bitcoin slips 0.20% near $75,800 as volume plunges and extreme fear persists
- Bitcoin.com NewsNubank and Mercadopago Suspend Crypto Withdrawals in Latam